Targeting fibroblast growth factor receptor 3 enhances radiosensitivity in human squamous cancer cells

K. Uzawa, T. Ishigami, K. Fushimi, T. Kawata, K. Shinozuka, A. Kasamatsu, Y. Sakamoto, K. Ogawara, M. Shiiba, H. Bukawa, H. Ito, H. Tanzawa

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Conventional therapies including radiation therapy cannot cure squamous cell carcinoma (SCC), and new treatments are clearly required. Our recent studies have shown that SCC cell lines exhibiting radioresistance show significant upregulation of the fibroblast growth factor receptor 3 (FGFR3) gene. We hypothesized that inhibiting FGFR3 would suppress tumor cell radioresistance and provide a new treatment approach for human SCCs. In the present study, we found that RNA interference-mediated FGFR3 depletion in HSC-2 cells, a radioresistant cell line, induced radiosensitivity and inhibited tumor growth. Use of an FGFR3 inhibitor (PD173074) obtained similar results with suppression of the autophosphorylation extracellular signal-regulated kinase pathway in HSC-2 cells and lung cancer cell lines. Moreover, the antitumor growth effect of the combination of PD173074 and radiation in vivo was also greater than that with either drug alone or radiation alone. Our results provided novel information on which to base further mechanistic study of radiosensitization by inhibiting FGFR3 in human SCC cells and for developing strategies to improve outcomes with concurrent radiotherapy.

Original languageEnglish
Pages (from-to)4447-4452
Number of pages6
Issue number43
Publication statusPublished - 2011 Oct 27
Externally publishedYes


  • FGFR3
  • fibroblast growth factor receptor 3 gene
  • radiosensitivity
  • squamous cell carcinoma

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research


Dive into the research topics of 'Targeting fibroblast growth factor receptor 3 enhances radiosensitivity in human squamous cancer cells'. Together they form a unique fingerprint.

Cite this